SCHEMBL4569876

SCHEMBL4569876

CC(=O)c1sccc1NS(=O)(=O)c1ccc(-c2cnn(C)c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.50
HPGD P15428 1/20 0.50
TSHR P16473 1/20 0.50
UCHL1 P09936 1/20 0.42
USP30 Q70CQ3 1/20 0.42
BRD4 O60885 1/20 0.42
TRIM24 O15164 1/20 0.41
ACLY P53396 1/20 0.40
SCN9A Q15858 1/20 0.40
NPSR1 Q6W5P4 4/20 0.40
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
KIT P10721 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
CCNA2 P20248 2/20 0.39
CDK2 P24941 2/20 0.39
HDAC3 O15379 1/20 0.38
KDM1A O60341 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4569886 0.87 TRIM24 (0.49) LMNAHPGDTSHRBRD4TRIM24
SCHEMBL13552620 0.83 LMNA (0.45) LMNAHPGDTSHRUCHL1USP30
SCHEMBL4569889 0.82 BRD4 (0.48) LMNAHPGDTSHRBRD4NPSR1
SCHEMBL4569877 0.78 TSHR (0.56) LMNAHPGDTSHRACLYNPSR1
SCHEMBL10068133 0.78 LMNA (0.38) LMNAHPGDTSHRUCHL1USP30
SCHEMBL4569880 0.77 NRP1 (0.51)
SCHEMBL4572322 0.76 NRP1 (0.53)
SCHEMBL4569896 0.75 NRP1 (0.54)
SCHEMBL4569878 0.72 BRD4 (0.50) LMNAHPGDTSHRBRD4ACLY
SCHEMBL13552671 0.72 TRIM24 (0.42) LMNAHPGDTSHRBRD4TRIM24

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8227606-B2 Arginine derivatives with NP-1 antagonistic activity ARK THERAPEUTICS, LTD. (GB) 2012-07-24 US disclosed
US-20120122862-A1 ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY GB06/019611.7 THERAPIES LIMITED (GB) 2012-05-17 US disclosed
US-8158789-B2 Arginine derivatives with NP-I antagonistic activity Ark Therapeutics Group Ltd. (GB) 2012-04-17 US disclosed
US-20100022525-A1 Arginine Derivatives with NP-I Antagonistic Activity GB06/019611.7 THERAPIES LIMITED (GB) 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122862-A1 ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY NPFFR1, NPR1, ARG1 LMNA 4551/4885HPGD 529/4885TSHR 801/4885
US-20100022525-A1 Arginine Derivatives with NP-I Antagonistic Activity NPFFR1, NPR1, ARG1 LMNA 4551/4885HPGD 529/4885TSHR 801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.